Clinical Trial Update: ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated ABT-348 as a standalone therapy and in combination with azacitidine for advanced hematologic malignancies; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• B-cell Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• ABT-348
• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 1 | Status: COMPLETED